Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped obesity management by producing clinically meaningful weight loss, primarily through appetite suppression and reduced energy intake. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.